{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2017"],"condition":["Colorectal cancer metastatic","Metastatisk, ikke-resektabel og kemo-refraktær kolorektal-kræft","Metastatic, non-resectable and chemo-refractory colorectal cancer"],"disease":["Metastatisk, Ikke-resektabel Og Kemo-refraktær Kolorektal-kræft","Metastatic, Non-resectable And Chemo-refractory Colorectal Cancer","Colorectal Cancer Metastatic"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2536542"],"location":["Denmark"],"study_start_month":["4"],"keyword":["Lonsurf","Avastin"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Lonsurf - RII\nLonsurf (TAS-102) with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer.\n\nA randomized phase II study","description":"Primary objective:\n• Progression-free survival (PFS)\nPrimary end-point:\n• Progression-free survival (PFS)","dates":{"creation":"2017-04-15"},"accession":"2536542","cross_references":{"EU Clinical Trials Register":["2016-005241-23"]}}